BioSenic SA Logo

BioSenic SA

ISIN: BE0974280126 | Ticker: BIOS | LEI: 549300HFIIMTOP1DFR76

About BioSenic SA

Company Description

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.

Our expertise is focused on bone cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for bone and autoimmune and inflammatory diseases.

BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.

Year founded

2006

Served area

Worldwide

Headquarters

Bâtiment H (bte 24) Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Hainaut – Belgium

Filings & Publications

2021

Report Q1 H1 Q3 FY
Consolidated Report ENG FRA
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Shareholder information

Shares outstanding

31,229,152

IPO

Feb. 6, 2015

Stock exchange(s)

Euronext Brussels

Contact Investor Relations department

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.